Treatment.com International Inc. (“Treatment” or the “Company”) (CSE: TRUE; OTC: TREIF; FFA 939) is a global healthcare technology company that has developed a next-generation AI platform to help clinicians and patients around the world make better health decisions.
Today, Treatment announces the beta release of its much-anticipated Treatment Digital Health App. This app is powered by Treatment’s proprietary AI engine which is trained and continually updated by doctors worldwide.
“Healthcare is complicated but using our digital health app is easy. I want our app to provide comfort to busy moms, dads and others because it delivers up to the minute clinical information in this rapidly changing world,” says John Fraser, CEO of Treatment. “Once the beta is complete our customers will be able to tap into the latest, Google-scale medical intelligence, to accurately assess their medical problems in the privacy of their homes, so they can make intelligent decisions about next steps.”
With Covid and emerging Delta and Omicron variations, people concerned about their health want simple to use, continually updated mobile apps that can help them figure out what their symptoms may be caused by. To provide this type of service Treatment has assembled a global team of doctors working around the clock to provide this information to everyone.
Treatment Digital Health App is physician-built and powered by Treatment’s AI engine, which sits at the heart of Treatment’s innovative Global Library of Medicine (GLM). The GLM is an advanced medical intelligence platform consisting of global diagnoses and treatment protocols, which will be integrated into products designed to offer improved patient safety, cost of care, prevention, and overall healthcare outcomes.
Treatment Digital Health App will provide a more robust, and more personalized approach to health recommendations to the approximately one billion people turning to Google every day to find answers to their health concerns.
The Treatment Digital Health app is being released to an exclusive group of beta testers, with plans to collect feedback towards a US launch in the new year. If you are interested in helping us, please email us at: [email protected].